Clinical pharmacology of etoricoxib

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 2, 2005, Pages 269-282

  Capone, Marta L ^a   Tacconelli, Stefania ^a   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

acute gouty arthritis; acute pain; cardiovascular toxicity; chronic low back pain; chronic musculo skeletal pain; COX 2; coxibs; etoricoxib; gastrointestinal toxicity; nonsteroidal anti inflammatory drugs; osteoarthritis; primary dysmenorrhoea; renal toxicity; rheumatoid arthritis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; PYRIDINE DERIVATIVE; SULFONE;

CLINICAL TRIAL; HUMAN; REVIEW;

CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PYRIDINES; SULFONES;

EID: 33645672376     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.2.269     Document Type: Review

References (70)

1. FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345:433-442. (Pubitemid 32747607)
2. PATRONO C, PATRIGNANI P, GARCA RODRIGUEZ LA: Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical readouts. J. Clin. Invest. (2001) 108:7-13. (Pubitemid 32634915)
3. CROFFORD LG: COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. (1997) 24:15-19.
4. DUBOIS RN, ABRAMSON SB, CROFFORD L et al.: Cyclooxygenase in biology and disease. FASEB J. (1998) 12:1063-1073. (Pubitemid 28418937)
5. SMITH WL, LANGENBACH R: Why there are two cyclooxygenase isozymes. J. Clin. Invest. (2001) 12:1491-1495. (Pubitemid 32574631)
6. VANE JR: Towards a better aspirin. Nature (1994) 367:215-216.
7. MARNETT LJ, ROWLINSON SW, GOODWIN DC, KALGUTKAR AS, LANZO CA: Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. (1999) 13:22903-22906.
8. DENNIS EA: Phospholipase A2 in eicosanoid generation. Am. J. Respir. Crit. Care Med. (2000) 161:S32-S35.
9. FITZPATRICK FA, SOBERMAN R: Regulated formation of eicosanoids. J. Clin. Invest. (2001) 107:1347-1351. (Pubitemid 32522026)
10. ROCCA B, SPAIN LM, PURE E, LANGENBACH R, PATRONO C, FITZGERALD GA: Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. Clin. Invest. (1999) 103:1469-1477. (Pubitemid 29535503)
11. YAMAGATA K, ANDREASSON KI, KAUFMANN WE, BARNES CA, WORLEY PF: Expression of a mitogeninducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron (1993) 11:371-386. (Pubitemid 23250354)
12. KNISS DA: Cyclooxygenases in reproductive medicine and biology. J. Soc. Gynecol. Investig. (1999) 6:285-292. (Pubitemid 30009759)
13. HARRIS RC, MCKANNA JA, AKAI Y, JACOBSON HR, DUBOIS RN, BREYER MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. (1994) 94:2504-2510. (Pubitemid 24379628)
14. VIO CP, CESPEDES C, GALLARDO P, MASFERRER JL: Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension (1997) 30:687-692. (Pubitemid 27444256)
15. FERRERI NR, AN SJ, MCGIFF JC: Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am. J. Physiol. (1999) 277:F360-F368. (Pubitemid 29459648)
16. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899. (Pubitemid 29272670)
17. TACCONELLI S, CAPONE ML, SCIULLI MG, RICCIOTTI E, PATRIGNANI P: The selectivity of novel COX-2 inhibitors in human whole blood assays of COX-isozyme activity. Curr. Med. Res. Opin. (2002) 18:503-511. (Pubitemid 36133053)
18. PATRIGNANI P, CAPONE ML, TACCONELLI S: Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin. Pharmacother. (2003) 4:265-284. (Pubitemid 36240466)
19. PATRIGNANI P, CAMPESTRINI J, BRANSON J et al.: Lumiracoxib is a selective inhibitor of cyclooxygenase-2 in patients with osteoarthritis. Ann. Rheum. Dis. (2004) 63:368.
20. BOMBARDIER C, LAINE L, REICIN A et al.: A double-blind comparison of rofecoxib and naproxen on the incidence of clinically important upper gastrointestinal events: the VIGOR Trial. N. Engl. J. Med. (2000) 343:1520-1528.
21. SCHNITZER TJ, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364:665-674. (Pubitemid 39140622)
22. MCADAM BF, CATELLA-LAWSON F, MARDINI IA, KAPOOR S, LAWSON JA, FITZGERALD GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA (1999) 96:272-277. (Pubitemid 29036089)
23. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA (2000) 284:1247-1255.
24. RIENDEAU D, PERCIVAL MD, BRIDEAU C et al.: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. (2001) 296:558-566. (Pubitemid 32112486)
25. MATSUMOTO AK, MELIAN A, MANDEL DR et al.: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumat. (2002) 29:1623-1630. (Pubitemid 34831233)
26. MALMSTROM K, SAPRE A, COUGLIN H et al.: Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin. Ther. (2004) 26:667-679. (Pubitemid 38736957)
27. DALLOB A, HAWKEY CJ, GREENBERG H et al.: Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Pharmacol. (2003) 43:573-585. (Pubitemid 36613116)
28. AGRAWAL NGB, PORRAS AG, MATTHEWS CZ et al.: Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J. Clin. Pharm. (2001) 41:1006-1110.
29. AGRAWAL NGB, MATTHEWS CZ, ROSE MJ et al.: Single-and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in healthy subjects. Clin. Pharmacol. Ther. (2002) 71:51.
30. RODRIGUES AD, HALPIN RA, GEER LA et al.: Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab. Dispos. (2003) 31:224-232. (Pubitemid 36159615)
31. CHAURET N, YERGEY JA, BRIDEAU C et al.: In vitro metabolism consideration, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg. Med. Chem. Letters (2001) 11:1059-1062. (Pubitemid 32319980)
32. KASSAHUN K, MCINTOSH IS, SHOU M et al.: Role of human liver cytochrome P4503a in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Met. Disp. (2001) 29:813-820. (Pubitemid 32488637)
33. TANG C, SHOU M, MEI Q, RUSHMORE TH, RODRIGUEZ AD: Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. (2000) 298:453-459. (Pubitemid 30244094)
34. CHESNE C, GUYOMARD C, GUILLOUZO A, SCHMID J, LUDWIG E, SAUTER T: Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotics (1998) 28:1-13. (Pubitemid 28051312)
35. HAMMAN MA, THOMPSON GA, HALL SD: Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Phar. (1997) 54:33-41. (Pubitemid 27353220)
36. DE LEPELEIRE I, GOTTESDIENER K, SHAHANE A, AGRAWAL N, LENS S: MK-0663 (Etoricoxib), a COX-2 inhibitor, did not affect predisolone/prednisone plasma levels in healthy volunteers. VII World Conference on Clinical Pharmacology and Therapeutics. IUPHAR. Florence, Italy (2000):455.
37. TACCONELLI S, CAPONE ML, PATRIGNANI P: Clinical pharmacology of novel selective COX-2 inhibitors. Curr. Pharm. Des. (2004) 10:589-601. (Pubitemid 38292386)
38. GOTTESDIENER K, SCHNITZER T, FISHER C et al.: Results of a randomized dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (2002) 41:1052-1061.
39. LEUNG AT, MALMSTROM K, GALLACHER AE et al.: Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, doubleblind, placebo and active-comparator controlled 12-week efficacy trial. Curr. Med. Res. Opin. (2002) 18:49-58. (Pubitemid 34475340)
40. ZACHER J, FELDMAN D, GERLI R et al.: A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr. Med. Res. Opin. (2003) 19:725-736. (Pubitemid 37466143)
41. WIESENHUTTER CW, BOICE JA, KO A et al.: Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebocontrolled trial. Mayo Clin. Proc. (2005) 80:470-479. (Pubitemid 40471378)
42. COLLANTES E, CURTIS S, LEE KW et al.: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam. Prac. (2002) 3:10-20.
43. SCHUMACHER HR, BOICE JA, DAIKH DI et al.: Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Biol. Med. J. (2002) 321:1488-1492. (Pubitemid 34666615)
44. RUBIN BR, BURTON R, NAVARRA S et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout. Arthritis Rheum. (2004) 50:598-606. (Pubitemid 38202232)
45. GOSSEC L, VAN DER HEIJDE D, MELIAN A et al.: The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann. Rheum. Dis. (2005) (In Press).
46. VAN DER HEIJDE D, BARAF HSB, RAMOS-REMUS C et al.: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. (2005) 52:1205-1215. (Pubitemid 40530128)
47. MALMSTROM K, KOTEY P, COUGHLIN H, DESJARDINS PJ: A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin. J. Pain. (2004) 20:147-155. (Pubitemid 38544033)
48. MALMSTROM K, ANG J, FRICKE J et al.: The analgesic effect of etoricoxib relative to that of two opioidacetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain. Curr. Med. Res. Opin. (2005) 21:141-149. (Pubitemid 40327516)
49. MALMSTROM K, KOTEY P, CICHANOWITZ N, DANIELS S, DESJARDINS PJ: Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol. Obstet. Invest. (2003) 56:65-69. (Pubitemid 37100222)
50. PALLAY R, SEGER W, ADLER J et al.: Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low-back pain: a 3 month, randomized, controlled trial. Scand. J. Rheumatol. (2004) 33:257-266. (Pubitemid 39180171)
51. BIRBARA CA, PUOPOLO AD, MUNOZ DR et al.: Treatment of chronic low back pain with etoricoxib, a new cyclooxygenase- 2 selective inhibitor: improvement in pain and disability - a randomized, placebo-controlled, 3-month trial. J. Pain (2003) 4:307-315. (Pubitemid 37013021)
52. HUNT RH, HARPER S, WATSON DJ et al.: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am. J. Gastroenterol. (2003) 98:1725-1733. (Pubitemid 36959151)
53. HUNT RH, HARPER S, CALLEGARI P et al.: Complementary studies of the gastrointestinal safety of the cyclooxygenase- 2-selective inhibitor etoricoxib. Aliment. Pharmacol. Ther. (2003) 17:201-210. (Pubitemid 36174250)
54. BRATER DC, HARRIS C, REDFERN JS, GERTZ BJ: Renal effects of COX-2- selective inhibitors. Am. J. Nephrol. (2001) 21:1-15. (Pubitemid 32238607)
55. CURTIS SP, NG J, YU Q et al.: Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin. Ther. (2004) 26:70-83. (Pubitemid 38241524)
56. FITZGERALD GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Rev. (2003) 2:879-891.
57. CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296:539-541. (Pubitemid 34408674)
58. KOBAYASHI T, TAHARA Y, MATSUMOTO M et al.: Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoEdeficient mice. J. Clin. Invest. (2004) 114:784-794. (Pubitemid 39578737)
59. WONG D, WANG M, CHENG Y, FITZGERALD GA: Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. (2005) 5:204-210. (Pubitemid 40378754)
60. CATELLA-LAWSON F, MCADAM B, MORRISON BW et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. (1999) 289:735-741. (Pubitemid 29191226)
61. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352:1092-1102. (Pubitemid 40365350)
62. SOLOMON SD, MCMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352:1071-1080. (Pubitemid 40365348)
63. NUSSMEIER NA, WHELTON AA, BROWN MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. (2005) 352:1081-1091. (Pubitemid 40365349)
64. GRAHAM DJ, CAMPEN D, HUI R et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (2005) 365:475-481. (Pubitemid 40215729)
65. CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. (2001) 345:1809-1817.
66. HIPPISLEY-COX J, COUPLAND C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ (2005) 330:1366.
67. http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4090B2-01-Merck- Etoricoxib.pdf EDGE trial.
68. http://www.ukmicentral.nhs.uk/headline/database/story.asp?NewsID=3982
69. http://www.trends-in-medicine.com/ Nov2004/Vioxx114qp.pdf MEDAL study
70. http://cox2.typepad.com/